linjc16/ctgov huggingface dataset:
Amniotic Fluid Sludge in Cerclage Patients as an Indicator for Increased Risk of Preterm Delivery and Neonatal Outcome.

Study Overview
=================
Brief Summary
-----------------
Amniotic Fluid Sludge Does Not Increase Risk of Preterm Delivery in Cerclage Patients.

Detailed Description
-----------------
177 patients were selected from a data base of 1890. 60 patients had sludge, 117 did not have sludge. Conclusion AF sludge on ultrasound had no association with increased risk of preterm delivery in patients with cerclage.

Official Title
-----------------
Amniotic Fluid Sludge in Cerclage Patients as an Indicator for Increased Risk of Preterm Delivery and Neonatal Outcome.

Conditions
-----------------
High Risk Pregnancy, Incompetent Cervix, Cerclage, Amniotic Fluid Sludge, Gestation Age at Delivery.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cerclage Pregnancy Outcome data available Neonatal Outcome data available Pre and Post Cerclage Cervical length measurements Hx of cervical procedures, if any, available Exclusion Criteria: Cervical ultrasound picture(s) unacceptable Any missing maternal or fetal data as stated above Fetal anomaly Cervical dilation at time of cerclage Placental previa or abruption Preterm Labor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AF Sludge as a predictor of preterm delivery in cerclage patients |  | 7 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absence of AF Sludge as a predictor of preterm delivery in cerclage patients |  | 7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Amniotic Fluid Sludge, Cerclage, Ultrasound, Preterm Delivery, Neonatal
AC-11 Supplement and Biological Aging

Study Overview
=================
Brief Summary
-----------------
This is a prospective non-randomized clinical study of 24 patients to evaluate the effects of the AC-11®. The study will evaluate the effectiveness of the supplement's ability to reverse epigenetic markers of biological age. The duration of the study will be 6 months.

Official Title
-----------------
Investigation of AC-11® Supplementation in Reversing Epigenetic Markers of Biological Aging Including Those Related to Telomere Length

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Dietary Supplement: AC-11


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women of any ethnicity. Age Range 55 years and older The patient must be able to comply with the treatment plan and laboratory tests Exclusion Criteria: Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision No immune system issues or immunodeficiency disease No history of viral illness which could be reactivated by immune downregulation Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) Diagnosis of a transient ischemic attack in the 6 months prior to screening Patients infected with hepatitis C or HIV Patients with Body Mass Index (BMI) > 40 kg/m2 Presence of active infection Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study Unable or unwilling to provide a required blood sample for testing As for the male-participants they are recommended to avoid fertilization for the first 6 months after the clinical trial. If the patient has previously used AM/PM HealthSpan system supplements at any time before the start of the trial.

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: prospective, non-randomized
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AC-11<br>6 months of treatment with AC-11 | Dietary Supplement: AC-11<br>* 6-months of treatment with AC-11<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Methylation age clock testing | Epigenetic testing | Change in epigenetic age from baseline to 6 months | 
| Telomere Test | Epigenetic testing | Change in telomere length from baseline to 6 months |
Flavonoids and Cardiovascular Disease

Study Overview
=================
Brief Summary
-----------------
To determine the association between flavonoids intake and the prevention of incident cardiovascular disease (CVD).

Detailed Description
-----------------
BACKGROUND: Basic science, clinical observation, and epidemiologic studies have all contributed to an emerging body of evidence on the potential role of flavonoids, a group of polyphenolic compounds with antioxidant properties, in the prevention of cardiovascular disease. However, the few existing studies on flavonoids or its food sources have provided inconsistent results, usually focusing on the primary prevention of coronary heart disease mortality. The study used the small grant mechanism (R03) to analyze previously collected data. DESIGN NARRATIVE: The investigators examined whether flavonoid intake was associated with the risk of incident CVD, and whether specific food sources of flavonoids--including tea, onions, apples, red wine, and other foods--were associated with the risk of incident CVD. The investigators processed and analyzed previously collected data of 39,876 middle-aged and older women free of CVD; the Women's Antioxidant Cardiovascular Study (WACS), a prospective study of 8,171 middle-aged and older women with pre-existing CVD or more than three coronary risk factors; the Normative Aging Study (NAS), a prospective study of 2,280 middle-aged and older men; and the Boston Area Health Study (BAHS), a case-control study of first nonfatal myocardial infarction in men and women aged less than 76 years. Using data from semiquantitative food frequency questionnaires administered in each study, the investigators determined individual intake of flavonoids and its food sources. Unlike previous studies, they examined flavonoids in relation to both the primary and secondary prevention of incident cardiovascular disease (CVD), consisting of confirmed cases of nonfatal myocardial infarction (Ml), nonfatal stroke, revascularization procedures, and CVD death. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Myocardial Infarction, Coronary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases

Study Overview
=================
Brief Summary
-----------------
Multicentric study, open label, uncontrolled phase IV in 30 patients with meibomian glands dysfunction . Its objective is to Collect information from patients and ophthalmologists specialized in ocular surface and eyelids to anticipate how Blephasteam ® can be optimized. This study involves 2 visits, visit of Inclusion, J0, then end of study visit, D21. Between the two visits patients will be treated with Blephasteam ® for 21 days (up to two uses per day) and complete a questionnaire every two days during the first week and then once a week the next two weeks.

Official Title
-----------------
Phase IV Multicentric Study, 30 Patients Suffering of Meibomian Glands Dysfunction.

Conditions
-----------------
Eyelid Diseases

Intervention / Treatment
-----------------
* Device: Blephasteam


Participation Criteria
=================
Eligibility Criteria
-----------------
Signed and dated informed consent. Male or female up to 4 years old. Known and treated symptomatic Meibomian Gland Diseases, and/or Dry Eye related to MGDs stable since at least a month. Without any active pathology requiring a change in ocular treatments within the last month before inclusion. Best corrected far visual acuity (VA) > 1/10

Ages Eligible for Study
-----------------
Minimum Age: 4 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Blephasteam|Eye lid warming goggles|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Meibomian Gland Dysfunction
The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids

Study Overview
=================
Brief Summary
-----------------
Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and obese people.

Detailed Description
-----------------
To assess and compare the effects of administration of Cissus quadrangularis (Linn) and a Cissus quadrangularis /Irvingia gabonensis combination on body weight blood pressure, fasting blood glucose, plasma total and LDL cholesterol in 72 overweight and obese subjects. The study was a 10 week randomized, double-blind, placebo-controlled design, involving 72 obese or overweight participants. Participants were randomly divided into three groups (24 participants/ group): Group 1 - Placebo; Group 2 - Cissus quadrangularis (CQ); Group 3 - Cissus quadrangularis and Irvingia gabonensis (CQ-IG). The placebo (250mg) or active formulations ((150 mg CQ and 250 mg CQ-IG) were administered twice daily before meals. Weight as well as fasting blood was taken at baseline, and at 4, 8 and 10 weeks. No major dietary changes or exercises were suggested during the study.

Official Title
-----------------
The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases

Conditions
-----------------
Obesity, Overweight, Dyslipidemia

Intervention / Treatment
-----------------
* Dietary Supplement: Irvingia/cissus combo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI>26kg/m2 Exclusion Criteria: Diabetics Pregnant and lactating Subjects on any other weight loss program Following any specific low calorie diet

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Comparison of actives for synergy | Dietary Supplement: Irvingia/cissus combo<br> <br> * Other names: Irvingia cissus combo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight change |  | 10 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood lipids Body fat Fasting blood glucose |  | 10 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antiobesity, Weight loss
An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks

Study Overview
=================
Brief Summary
-----------------
The participant is being asked to take part in this trial, because the participant is a survivor of childhood cancer. Primary Objective To evaluate remote cardiomyopathy prediction via smartwatch and one clinical ECG and assess the concordance of the two ECGs in terms of predicted risk. Secondary Objective To build a novel predictive model solely on smartwatch ECG to predict risk for cardiomyopathy.

Detailed Description
-----------------
The proposed study is looking to compare the 30 second ECG read from a smartwatch to the clinical ECG during a SJLIFE scheduled ECG appointment.

Official Title
-----------------
An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks

Conditions
-----------------
Childhood Cancer, Cardiomyopathy, Primary

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SJLIFE participant and 22 years of age or older at time of enrollment Participant or legal guardian is able and willing to give informed consent At least 5 years after childhood cancer diagnosis Exclusion Criteria: Been diagnosed with cardiomyopathy on previous SJLIFE ECG Currently on heart medication

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pediatric Childhood Cancer Survivors<br>The comparison of two ECGs in terms of predictive risk. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Standard 12-lead ECG | To be obtained during SLIFE Human Performance Lab appointment. Participant will receive a resting (supine) 12-lead ECG using a GE Mac 2000 Resting ECG System (General Electric Healthcare, Milwaukee, WI, USA). This will be assessed with the Apple Smartwatch ECG recording to determine concordance of the two ECGs. | Baseline | 
| Apple Smartwatch ECG 30-second recording | To be obtained during the SLIFE Human Performance Lab appointment, collected immediately after recording of the standard 12-lead ECG. A study team member will place an Apple Smartwatch Series 7 on the participant's wrist. The participant will be instructed to start the ECG, which will be a 30-second recording process. Once captured, the data will be automatically transferred to the IOS application on the study iPhone. This will be assessed with the standard 12-lead ECG recording to determine concordance of the two ECGs. | Baseline |
Open Bifurcation Surgery Study

Study Overview
=================
Brief Summary
-----------------
Different cross clamping techniques in aortic surgery causes different cardiac stress

Official Title
-----------------
Evaluation of Cardiac Function in Different Techniques in Infrarenal Aortic Surgery

Conditions
-----------------
Infrarenal Aortic Aneurysm

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: AAA > 5cm Exclusion Criteria: emergency cases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| sectional cross clamping<br> | |
| simultaniously cross clamping<br> | |
| EVAR<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiac function with echocardiography |  | 2 years |
Effects of Exercise on Depression Symptoms, Physical Function, and Quality of Life in Community-Dwelling Elderly

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to investigate the effects of 8-week exercise training on depression symptoms, physical functions, and quality of life in the community-dwelling elderly.

Official Title
-----------------
Effects of Exercise on Depression Symptoms, Physical Function, and Quality of Life in Community-Dwelling Elderly

Conditions
-----------------
Healthy Elderly

Intervention / Treatment
-----------------
* Other: exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elderly subjects living in the community aged 65 years or older, sedentary lifestyle Exclusion Criteria: cancer, major neuromuscular disease, respiratory or cardiovascular disease which might affect exercise post myocardial infarction or major surgery in the previous year psychological disease

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: exercise<br> | Other: exercise training<br>* A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks<br>* Other names: exercise;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Taiwanese Geriatric Depression Scale (TGDS), Mini-Mental State Examination (MMSE), Groningen Activity Restriction Scale (GARS) |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short-form 36 (SF-36) |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, physical function, Quality of life
Impact of ESSURE Devices Withdrawal on the Symptomatology of Patients

Study Overview
=================
Brief Summary
-----------------
The ESSURE device is a method of permanent contraception, marketed in France since 2005. Multiple side effects have been reported by patients since 2015 and the marketing was stopped in 2017. For several months it was observed an increase in requests for withdrawal of these devices. The principal objective of this study is to evaluate clinical improvement and quality of life after ESSURE removal. This is a multicenter retrospective descriptive study involving the gynecology department of the Croix Rousse Hospital and the gynecology department of the Lyon Sud Hospital over a period of 1 year (1 January 2017-31 December 2017).

Official Title
-----------------
Impact of ESSURE Devices Withdrawal on the Symptomatology of Patients

Conditions
-----------------
Quality of Life, Contraceptive Device; Complications

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who underwent ESSURE removal due to suspected adverse effects of the device. Women who agreed to participate in the study Exclusion Criteria: - Women who underwent ESSURE removal to restore their fertility.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the clinical improvement after the intervention of withdrawal of ESSURE devices | This evaluation will be carried out thanks to a questionnaire. The 4th question retrospectively identifies the symptoms presented by patients. The proposed list of symptoms was established by reviewing the symptoms most often found in the medical records of the patients included. Question 11 evaluates the variation of each symptom after removal of ESSURE devices through an ordinal scale (total disappearance, significant improvement, poor improvement, no improvement, worsening). | One day at least one month after the procedure |